A detailed history of Pittenger & Anderson Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Pittenger & Anderson Inc holds 26,914 shares of ABBV stock, worth $5.3 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
26,914
Previous 26,554 1.36%
Holding current value
$5.3 Million
Previous $4.84 Million 4.53%
% of portfolio
0.2%
Previous 0.21%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$154.79 - $180.76 $55,724 - $65,073
360 Added 1.36%
26,914 $4.62 Million
Q1 2024

May 02, 2024

BUY
$159.82 - $182.1 $998,715 - $1.14 Million
6,249 Added 30.78%
26,554 $4.84 Million
Q4 2023

Feb 02, 2024

BUY
$137.6 - $154.97 $1.51 Million - $1.7 Million
10,976 Added 117.65%
20,305 $3.15 Million
Q3 2023

Nov 02, 2023

BUY
$133.59 - $154.65 $4,675 - $5,412
35 Added 0.38%
9,329 $1.39 Million
Q2 2023

Aug 09, 2023

SELL
$132.51 - $164.9 $13,648 - $16,984
-103 Reduced 1.1%
9,294 $1.25 Million
Q1 2023

May 10, 2023

BUY
$144.61 - $166.54 $16,340 - $18,819
113 Added 1.22%
9,397 $1.5 Million
Q4 2022

Feb 10, 2023

BUY
$138.31 - $165.87 $192,804 - $231,222
1,394 Added 17.67%
9,284 $1.5 Million
Q3 2022

Nov 15, 2022

BUY
$134.21 - $153.93 $406,924 - $466,715
3,032 Added 62.41%
7,890 $1.06 Million
Q2 2022

Jul 14, 2022

BUY
$137.62 - $174.96 $304,415 - $387,011
2,212 Added 83.6%
4,858 $744,000
Q1 2022

Apr 28, 2022

BUY
$131.98 - $163.75 $659 - $818
5 Added 0.19%
2,646 $429,000
Q4 2021

Feb 10, 2022

BUY
$107.43 - $135.93 $136,758 - $173,038
1,273 Added 93.06%
2,641 $358,000
Q3 2021

Nov 12, 2021

BUY
$106.4 - $120.78 $62,350 - $70,777
586 Added 74.94%
1,368 $148,000
Q2 2021

Aug 13, 2021

BUY
$105.21 - $117.21 $8,627 - $9,611
82 Added 11.71%
782 $88,000
Q4 2020

Feb 11, 2021

SELL
$80.49 - $108.67 $40,245 - $54,335
-500 Reduced 41.67%
700 $75,000
Q3 2020

Nov 10, 2020

SELL
$85.91 - $100.83 $25,773 - $30,249
-300 Reduced 20.0%
1,200 $105,000
Q2 2020

Aug 13, 2020

SELL
$73.37 - $98.18 $18,342 - $24,545
-250 Reduced 14.29%
1,500 $147,000
Q1 2020

Apr 30, 2020

SELL
$64.5 - $97.79 $52,567 - $79,698
-815 Reduced 31.77%
1,750 $133,000
Q4 2019

Feb 12, 2020

SELL
$72.13 - $90.25 $7,213 - $9,025
-100 Reduced 3.75%
2,565 $227,000
Q3 2019

Nov 14, 2019

SELL
$62.98 - $75.72 $162,803 - $195,736
-2,585 Reduced 49.24%
2,665 $202,000
Q2 2019

Aug 09, 2019

SELL
$65.7 - $83.98 $307,476 - $393,026
-4,680 Reduced 47.13%
5,250 $382,000
Q1 2019

May 10, 2019

SELL
$77.14 - $90.79 $11,956 - $14,072
-155 Reduced 1.54%
9,930 $800,000
Q4 2018

Feb 14, 2019

SELL
$77.85 - $96.01 $1.32 Million - $1.62 Million
-16,915 Reduced 62.65%
10,085 $930,000
Q3 2018

Oct 12, 2018

SELL
$88.91 - $98.84 $15,559 - $17,297
-175 Reduced 0.64%
27,000 $2.55 Million
Q2 2018

Aug 15, 2018

BUY
$89.78 - $106.23 $1.26 Million - $1.49 Million
14,060 Added 107.21%
27,175 $2.52 Million
Q1 2018

May 08, 2018

BUY
$92.01 - $123.21 $271,889 - $364,085
2,955 Added 29.08%
13,115 $1.24 Million
Q4 2017

Feb 13, 2018

BUY
$89.56 - $98.21 $26,868 - $29,462
300 Added 3.04%
10,160 $983,000
Q3 2017

Nov 13, 2017

SELL
$69.85 - $89.22 $5,238 - $6,691
-75 Reduced 0.75%
9,860 $876,000
Q2 2017

Aug 10, 2017

BUY
N/A
9,935
9,935 $720,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $348B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Pittenger & Anderson Inc Portfolio

Follow Pittenger & Anderson Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pittenger & Anderson Inc, based on Form 13F filings with the SEC.

News

Stay updated on Pittenger & Anderson Inc with notifications on news.